#Orsini #gene therapies #Genetix Biotherapeutics

Orsini Expands Gene Therapy Distribution

Orsini, recognized as a leader in the field of rare disease pharmacy solutions, has taken a significant step forward by joining forces with Genetix Biotherapeutics Inc. as a specialty pharmacy partner. This partnership focuses on the distribution of three cutting-edge FDA-approved gene therapies—LYFGENIA™, ZYNTEGLO™, and SKYSONA™. These therapies offer new hope for patients suffering from rare genetic disorders, emphasizing Orsini's ongoing commitment to enhancing the accessibility of life-changing treatments.

Advancements in Gene Therapy

Incorporating these three innovative therapies, Orsini now supports the distribution of a total of twelve gene therapies through its Cell and Gene Therapy Center of Excellence. The newly added treatments include:

1. LYFGENIA™ (lovotibeglogene autotemcel): A pioneering therapy designed to treat patients aged 12 and older who suffer from sickle cell disease (SCD), particularly those with a history of vaso-occlusive events. This groundbreaking treatment works by adding a functional β-globin gene to the patient’s own blood stem cells, producing healthy adult hemoglobin and reducing the sickling of red blood cells.

2. ZYNTEGLO™ (betibeglogene autotemcel): The first and only FDA-approved therapy for treating adult and pediatric patients with β-thalassemia who rely on regular blood transfusions. This one-time treatment aims to eliminate the need for transfusions by enabling the production of normal hemoglobin levels in the patient's body.

3. SKYSONA™ (elivaldogene autotemcel): Approved specifically for boys aged 4 to 17 with early, active cerebral adrenoleukodystrophy (CALD), SKYSONA plays a critical role in slowing the progression of neurologic dysfunction in patients lacking a suitable donor for traditional stem cell transplant.

Impact on Patients

Brandon Tom, CEO of Orsini, expressed pride in supporting the introduction of these transformative treatments. He stated, “As the leading independent specialty pharmacy in cell and gene therapies, Orsini is honored to support bringing these transformative treatments to patients. With our deep experience in rare conditions and our unwavering commitment to patient care, this is a powerful step forward in delivering the promise of curative therapies to those who need it most.”

Orsini has been providing comprehensive patient care since 1987, and with this collaboration, the organization underscores its commitment to innovative therapies and improved patient outcomes. Orsini collaborates closely with biopharma innovators and healthcare providers to facilitate patient access to these revolutionary treatments, paving the way for future advancements in rare disease management.

The Future of Gene Therapies

The introduction of LYFGENIA, ZYNTEGLO, and SKYSONA not only represents a leap forward in the treatment of these debilitating conditions but also sets a precedent for future developments in gene therapy. These therapies highlight the potential of genetic modification to cure genetic diseases that were once deemed untreatable.

Orsini's emphasis on assuring that